Apelin Promotes Endothelial Progenitor Cell Angiogenesis in Rheumatoid Arthritis Disease via the miR-525-5p/Angiopoietin-1 Pathway

Ting-Kuo Chang1,2, You-Han Zhong3, Shan-Chi Liu4, Chien-Chung Huang5,6, Chun-Hao Tsai7,8, Hsiang-Ping Lee9,10, Shih-Wei Wang11,12,13, Chin-Jung Hsu8,9† and Chih-Hsin Tang3,5,14,15*

1 Department of Medicine, Mackay Medical College, New Taipei, Taiwan, 2 Division of Spine Surgery, Department of Orthopedic Surgery, Mackay Memorial Hospital, New Taipei, Taiwan, 3 Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan, 4 Department of Medical Education and Research, China Medical University Beigang Hospital, Yunlin, Taiwan, 5 School of Medicine, China Medical University, Taichung, Taiwan, 6 Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 7 Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan, 8 Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan, 9 School of Chinese Medicine, China Medical University, Taichung, Taiwan, 10 Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan, 11 Department of Medicine, Mackay Medical College, New Taipei City, Taiwan, 12 Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, 13 Institute of Biomedical Sciences, Mackay Medical College, Taipei, Taiwan, 14 Chinese Medicine Research Center, China Medical University, Taichung, Taiwan, 15 Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan

†These authors have contributed equally to this work
*Correspondence: chtang@mail.cmu.edu.tw

Specialty section:
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology

Keywords: apelin, angiopoietin-1, endothelial progenitor cells (EPC), rheumatoid arthritis, miR-525-5p

Angiogenesis is a critical process in the formation of new capillaries and a key participant in rheumatoid arthritis (RA) pathogenesis. The adipokine apelin (APLN) plays critical roles in several cellular functions, including angiogenesis. We report that APLN treatment of RA synovial fibroblasts (RASFs) increased angiopoietin-1 (Ang1) expression. Ang1 antibody abolished endothelial progenitor cell (EPC) tube formation and migration in conditioned medium from APLN-treated RASFs. We also found significantly higher levels of APLN and Ang1 expression in synovial fluid from RA patients compared with those with osteoarthritis. APLN facilitated Ang1-dependent EPC angiogenesis by inhibiting miR-525-5p synthesis via phospholipase C gamma (PLCγ) and protein kinase C alpha (PKCα) signaling. Importantly, infection with APLN shRNA mitigated EPC angiogenesis, articular swelling, and cartilage erosion in ankle joints of mice with collagen-induced arthritis. APLN is therefore a novel therapeutic target for RA.

Keywords: apelin, angiopoietin-1, endothelial progenitor cells (EPC), rheumatoid arthritis, miR-525-5p
INTRODUCTION

Rheumatoid arthritis (RA) is one of the most common autoimmune disorders, characterized by the accumulation of inflammatory cytokines in the synovial joint, resulting in pannus formation, cartilage degradation and bone destruction (1). Angiogenesis is a critical driver of RA disease, in which pre-existing blood vessels promote the entry of blood-derived leukocytes into the synovial tissues to facilitate and potentiate inflammation (2).

Endothelial progenitor cells (EPCs) develop from bone marrow-derived endothelial stem cells, which contain the cell surface markers CD133, CD34 and vascular endothelial growth factor receptor 2 (VEGFR2) and are capable of stimulating postnatal vasculogenesis (3) and angiogenic function (4). EPC proliferation and migration facilitate angiogenesis (4), enabling the development of RA (5, 6). EPC-dependent angiogenesis therefore seems to be a worthwhile treatment target in RA. EPC proliferation, migration and angiogenesis is regulated by the balance in activities between proangiogenic factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and angiopoietin-1 (Ang1), and antiangiogenic factors including thrombospondin-1 (7, 8). Ang1 plays a critical role in endothelial cell adhesion, migration and production during angiogenesis (9). However, the effects of Ang1 in EPC angiogenesis in RA disease are unclear.

Apelin (APLN) is a member of the adipokine superfamily that is expressed in different human tissues including nervous system, adipose and endothelial tissues (10, 11). APLN has been linked with numerous disorders, including cardiovascular and neurodegenerative diseases (10, 11). Emerging evidence has highlighted the association between APLN and arthritic diseases, including RA and osteoarthritis (OA), for example (12). Treating human chondrocytes with APLN increases the synthesis of matrix metalloproteinases (MMPs) and other catabolic factors (13). APLN also promotes the production of the proinflammatory cytokine interleukin 1 beta (IL-1β) in human OA synovial fibroblasts (OASFs) (14). In RA patients, levels of APLN expression are associated with the expression of the catabolic enzyme MMP-9 (15). These reports suggest that APLN is a novel avenue for treating arthritic diseases.

MiRNAs are single-stranded noncoding RNA molecules that manipulate gene expression at the post-transcriptional level (16). Various miRNA genes expressed in immune, inflammatory and synovial cells from patients with RA (17) can cause synovial hyperplasia and bone damage, or promote inflammation, through positive or negative manipulation (18). Recently, miRNAs have been found to regulate angiogenic activity in the progression of arthritic diseases (19, 20). However, it remains unclear as to how the APLN-miRNA axis regulates angiogenesis in RA disease. Our study has identified higher levels of APLN and Ang1 expression in patients with RA than in those with OA. APLN treatment increased RASF-derived Ang1 production and facilitated EPC angiogenesis by inhibiting miR-525-5p synthesis via phospholipase C gamma (PLCγ) and protein kinase C alpha (PKCα) signaling. Inhibition of APLN expression diminished Ang1-dependent angiogenesis and inhibited collagen-induced arthritis (CIA) in mice. APLN is therefore a novel therapeutic target for RA.

MATERIALS AND METHODS

Materials

APN, Ang1, PLCγ and PKCα antibodies were purchased from Santa Cruz Biotechnology (CA, USA). p-PLCγ and p-PKCα antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). All siRNAs (ON-TARGETplus) were obtained from Dharmacon Research (Lafayette, CO, USA). Taqman® one-step PCR Master Mix, qPCR primers and probes were obtained from Applied Biosystems (Foster City, CA, USA). β-Actin antibody and pharmacological inhibitors were obtained from Sigma-Aldrich (St. Louis, MO, USA).

Human Synovial Fluid Samples

Study approval was granted by the Institutional Review Board of China Medical University Hospital (Taichung, Taiwan) and all patients provided written informed consent before participating in the study. Synovial fluid samples were obtained from patients undergoing total knee arthroplasty for OA (n=20) or RA (n=20).

Cell Culture

Human RASFs were purchased from the Riken Cell Bank (Ibaraki, Japan). Primary human EPCs were isolated according to the procedure detailed in our previous reports (21, 22). Mouse osteoblastic cell line MC3T3-E1 were purchased from the American Type Culture Collection (Manassas, VA, USA). RASFs and EPCs were maintained in DMEM while MC3T3-E1 cells were cultured in α-MEM medium. The culture mediums were supplemented with 20 mM HEPES and 10% fetal bovine serum, 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C with 5% CO2.

Western Blot Analysis

RASF cells (5 × 10⁵ cells) were seeding in 6 well plate. Cell lysates were resolved by SDS-PAGE and transferred to Immobilon® PVDF membranes. Western blot analysis was performed according to the procedures detailed in our previous investigations (23–26).

Quantitative Real-Time PCR (qPCR) Analysis of mRNA and miRNA

Total RNA was extracted from RASFs and paws using TRIzol reagent and then reverse-transcribed into cDNA using oligo(dT) primers. For the miRNA assay, cDNA was synthesized using the TaqMan MicroRNA Reverse Transcription Kit. qPCR analysis was conducted according to an established protocol (27–29).

Preparation of Conditioned Medium (CM)

RASFs were plated in 6-well dishes and grown to confluence. The culture medium was exchanged with serum-free DMEM
medium. CM were collected 1 days after the change of media and stored at -20°C until use. In the series of experiments, cells were pretreated for 30 min with inhibitors, including U73122, GF109203X and Go6976 or transfected with miR-525-5p mimic, PLCγ, PKCα and PKCδ siRNA for 24 h followed by treatment with APLN for 24 h to prevent signaling via the APLN pathway.

**ELISA Assay**

RASFs were treated with pharmacological inhibitors then incubated with APLN for 24 h and the medium was quantified for Ang1 expression using a Ang1 ELISA kit (Peprotech, Rocky Hill, NJ, USA), following the manufacturer’s protocol.

**EPC Migration and In Vitro Tube Formation**

EPCs were treated with RASF conditioned medium (CM) for 24 h. EPC migration and in vitro tube formation were evaluated by the procedures detailed in our previous publication (30).

**The Chick Chorioallantoic Membrane Assay**

*In vivo* angiogenic activity was assessed using the chorioallantoic membrane (CAM) of the chick embryo, as described previously (6, 31). Fertilized chick embryos were incubated in an 80% humidified atmosphere at 37°C. All animal investigations adhered to approved protocols issued by the Institutional Animal Care and Use Committee of China Medical University (Taichung, Taiwan).

**In Vivo Matrigel Plug Assay**

Four-week-old nude male mice received a single subcutaneous injection of Matrigel containing RASF CM. Mice were subcutaneously injected with 300 µL of Matrigel. On day 7, the Matrigel plugs were harvested, partially fixed with 4% formalin, embedded in paraffin, and subsequently processed for immunohistochemistry staining for CD31, CD34, and CD133. Hemoglobin concentrations were measured, according to previously described methodology (6, 31, 32).

**CIA Mouse Model**

The CIA mouse model was performed according to the methodology detailed in our previous publications (6, 32, 33). After receiving two immunizations, the mice were given weekly intra-articular injections of ~7.1 × 10^6 plaque-forming units (PFU) of control or APLN short hairpin RNA (shRNA). Upon sacrifice after 49 days of treatment, phalanges and ankle joints were removed from each mouse then fixed in 4% paraformaldehyde for micro-computed tomography (micro-CT) analysis. Analysis was performed using CTAn 1.18.4 (Bruker micro-CT, Kontich, Belgium). First, we segmented the reaction area which showed less calcium content with porous structure. We then labelled the isolated reaction area with purple color.

**Statistical Analysis**

All statistical analyses were carried out using GraphPad Prism 5.0 (GraphPad Software) and all values are expressed as the mean ± S.D. Differences between selected pairs from the experimental groups were analyzed for statistical significance using the paired sample t-test for *in vitro* analyses and by one-way ANOVA followed by Bonferroni testing for *in vivo* analyses. *p < 0.05, **p < 0.01 and ***p < 0.001 versus the control group; #p < 0.05 versus the APLN-treated group.

**RESULTS**

**APLN Facilitates Ang1-Dependent EPC Angiogenesis**

APLN is associated with the progression of arthritic diseases, including RA (12). Ang1 is an important angiogenetic regulator in endothelial cell angiogenesis (9). First, we examined whether APLN promotes Ang1 synthesis in RASFs. Stimulation of RASFs with APLN dose-dependently increased Ang1 transcription and translation levels (Figures 1A, B) and also the secretion of Ang1 protein (Figure 1C). EPC tube formation and migration assays examined the effects of APLN-controlled angiogenesis in RASFs (5). CM from APLN-treated RASFs significantly increased the formation and reorganization of capillary-like network structures as well as migratory activity (VEGF-increased vessel formation served as the positive control) (Figures 1D, E). Treatment with Ang1 but not VEGF antibody, dramatically reduced the effects of CM from APLN-treated RASFs upon EPC tube formation and migration (Figures 1D, E), indicating that Ang1 is more important than VEGF in APLN-promoted EPC angiogenesis. To directly examine whether APLN acts as an angiogenic factor *in vivo*, the CAM assay was used. Matrigel was mixed with CM from APLN-treated RASFs and placed onto the surface of the CAMs. CM from APLN-treated RASFs synthesized new capillaries then control (VEGF-increased vessel formation served as the positive control) (Figure 1F), suggesting that APLN promotes Ang1 production in RASFs and enhances tube formation and migration of EPCs.

**High Levels of APLN and Ang1 Expression in RA Patients Induce EPC Homing and Angiogenesis**

Next, we investigated APLN and Ang1 levels in RA patients. We found markedly higher levels of APLN and Ang1 expression in synovial fluid from RA patients compared with OA synovial fluid samples (Supplementary Figures 1A, B). Synovial fluid levels of APLN and Ang1 were positively correlated (Supplementary Figure 1C). Next, we examined whether synovial fluid from RA patients promotes EPC homing and angiogenesis. Migratory activity, as well as the formation and reorganization of capillary-like network structures, was significantly greater in EPCs incubated with RA synovial fluid compared with EPCs incubated with OA synovial fluid (Supplementary Figures 1D, E). Treatment with Ang1 antibody dramatically diminished the effects of RA synovial fluid upon EPC migration and tube formation (Supplementary Figures 1D, E), indicating that high levels of APLN and Ang1 expression in RA patients induce EPC homing and angiogenesis.
FIGURE 1 | APLN increases Ang1 expression in RASFs and promotes EPCs tube formation and migration. (A–C) RASFs were incubated for 24 h with APLN. Ang1 expression was quantified by qPCR, Western blot and ELISA assays. (D, E) RASFs cells were treated with APLN doses in a manner for 24 h and collected conditioned medium (CM) was applied to endothelial progenitor cells (EPCs), then EPC migration and angiogenesis was measured. (F) Matrigel plugs containing CM from APLN-treated RASFs or VEGF (positive control) were applied to 6-day-old fertilized chick embryos for 4 days. CAMs were examined by microscopy and photographed, and vessels counted. *p < 0.05, **p < 0.01 and ***p < 0.001 versus the control group; #p < 0.05 versus the APLN-treated group.
PLCγ and PKCα Signaling Cascades Regulate APLN-Promoted Ang1 Expression and Angiogenesis in EPCs

PLC and PKC signaling pathways control different cellular functions, including angiogenesis (34). We therefore sought to determine how these pathways affect APLN-induced upregulation of Ang1 synthesis and EPC angiogenesis. Treatment of RASFs with a PLC inhibitor (U73122) or PLCγ siRNA reduced the effects of APLN upon Ang1 expression (Figures 2A, B) and inhibited APLN-induced upregulation of EPC migration and tube formation (Figures 2C, D). Incubating RASFs with APLN induced PLCγ phosphorylation (Figures 2E, F). In addition, the PKCα inhibitors (GF109203X and Go6976) and PKCα siRNA, but not the PKCδ inhibitor (Rottlerin) or PKCδ siRNA, abolished APLN-facilitated Ang1 expression and EPC angiogenesis (Figures 3A–D). Stimulation of RASFs with APLN also increased PKCα phosphorylation (Figure 3E). Thus, APLN promotes Ang1 expression in RASFs and enhances EPC angiogenesis via PLCγ and PKCα signaling.
Inhibition of miR-525-5p Controls APLN-Promoted Ang1 Synthesis and EPC Angiogenesis

The dysregulated expression of miRNAs in patients with RA differs from miRNA expression in healthy individuals (35, 36). Using open-source miRNA software (miRanda, https://bioweb.pasteur.fr/packages/pack@miRanda@3.3a/; Microt4, http://diana.imis.athena-innovation.gr/DianaTools/index.php?r= microt4/index; and miRWalk, http://mirwalk.umm.uni-heidelberg.de/), we identified 8 candidate miRNAs that could possibly bind to the 3'UTR region of Ang1 mRNA. Among these 8 miRNAs, levels of miR-525-5p expression were suppressed by the greatest extent after APLN administration (Figure 4A and Supplementary Figure S2). Treating RASFs with APLN concentration-dependently reduced miR-525-5p synthesis (Figure 4B). Transfection of RASFs with miR-525-5p mimic antagonized the effects of APLN upon Ang1 production and EPC angiogenesis (Figures 4C–E). Similarly, transfection with miR-525-5p mimic downregulated Ang-1 expression in mouse MC3T3-E1 cells (Supplementary Figure S3).

To examine whether miR-525-5p regulates ANG1 gene transcription, we constructed a luciferase reporter vector with the wild-type 3'UTR of ANG1 mRNA (WT-Ang1-3'UTR) and a mutated vector harboring mismatches in the predicted miR-525-5p binding
site (mt-Ang1-3’UTR) (Figure 4F). MiR-525-5p mimic reduced APLN-induced luciferase activity in the wt-Ang1-3’UTR plasmid, but not in the mt-Ang1-3’UTR plasmid (Figures 4G, H). Moreover, U73122, GF109203X and Go6976 all reversed APLN-induced inhibition of miR-525-5p expression (Figure 4I), indicating that PLCγ and PKCα signaling mediate APLN-induced inhibition of miR-525-5p.

Inhibition of APLN Reduces EPC Angiogenesis as Well as Arthritis Severity In Vivo
APLN shRNA was used to validate the in vivo role of APLN. Infection of RASFs with APLN shRNA reduced APLN and Ang1 levels (Figures 5A, B). Compared with RASF CM, APLN shRNA-infected RASF CM reduced EPC migration and tube
CAM and Matrigel investigations demonstrated that CM from RASFs enhanced vessel formation in vivo (Figures 5E, F), while APLN shRNA reduced RASF CM-promoted induction of vessel formation (Figures 5E, F). These results were confirmed by IHC staining of hemoglobin levels and the human-specific vessel marker CD31, as well as EPC markers CD34 and CD133 (Figures 5G, H).

Next, we used the CIA mouse model to investigate the therapeutic effect of inhibiting APLN in vivo. Compared with controls, CIA mice exhibited significant paw swelling that improved after administration of APLN shRNA (Figures 6A, B). Micro-CT images of the hind paws showed that APLN shRNA reversed CIA-induced reductions in bone mineral density (p<0.01), bone volume (p<0.0001) and trabecular numbers (p<0.0001) (Figures 6C–E). Moreover, CIA mice exhibited lower cartilage thicknesses, as indicated by H&E and Safranin-O/Fast-green staining (Figure 6F). APLN shRNA reversed CIA-induced cartilage degradation (Figure 6G). According to IHC staining data, levels of vessel marker (CD31) and EPC markers (CD34 and CD133) were all markedly higher in CIA mice than in controls.
Notably, APLN shRNA treatment antagonized CIA-induced upregulation of CD31, CD34 and CD133 expression (Figure 6G). Furthermore, the in vitro results were confirmed by qPCR assays, showing lower levels of APLN mRNA in the APLN-shRNA group compared with those in the CIA group, while levels of miR-525-5p were higher in the APLN-shRNA group than in the CIA group (Supplementary Figure S4). These results indicate that inhibiting APLN lowers EPC angiogenesis as well as disease activity in CIA-induced arthritis.

**DISCUSSION**

RA is well recognized for its manifestations of synovial inflammation and joint destruction (1, 37, 38). The development of RA disease relies upon pannus formation and neovascularization (2). Ang1 is a critical modulator during the physiological and pathological progression of angiogenesis (39). APLN reportedly increases IL-1β expression and VEGF-mediated angiogenesis, facilitating OA development (14, 19).
Here, we report finding higher APLN and Ang1 expression in patients with RA than in those with OA. Moreover, we found that APLN stimulates Ang1 synthesis in RASFs and facilitates EPC angiogenesis by inhibiting miR-525-5p synthesis via PLCγ and PKCα signaling. Importantly, inhibiting the expression of APLN reduces EPC angiogenesis, reducing the progression of RA in vivo.

EPCs also stimulate new vessel formation (40, 41) and promotion of EPC mobilization by angiogenic factors facilitates tumor development and angiogenesis (42). EPC angiogenesis plays a vital role in RA (5, 43). EPC infiltration into joints has been reported in the CIA-induced RA mouse model (5). Here, we observed that compared with OA synovial fluid, RA synovial fluid facilitates EPC infiltration and angiogenesis, indicating that EPC-dependent angiogenesis is an important step during RA progression. Levels of EPC-specific markers were higher in our CIA mouse model than in controls. APLN shRNA reduced levels of vessel markers and EPC markers and mitigated the severity of RA disease. Thus, inhibition of APLN shows promise as a novel strategy in RA disease, reducing EPC angiogenesis and disease development.

Various proangiogenic factors, including VEGF, fibroblast growth factor, PDGF and Ang, are involved in the angiogenic process of several different diseases, including arthritis (2). Interestingly, we found that Ang1 antibody significantly antagonized increases in EPC angiogenesis induced by RA synovial fluid, suggesting that Ang1 is a vital modulator in EPC-mediated angiogenesis during RA development. Incubation of RASFs with APLN concentration-dependently promotes Ang1 synthesis, resulting in EPC angiogenesis. Importantly, Ang1 antibody, but not VEGF antibody, abolished EPC migration and tube formation in CM from APLN-treated RASFs, indicating that Ang1 is more important than VEGF in APLN-induced angiogenesis during RA disease.

Activation of the PLC/PKC signaling cascade is essential for regulating various cellular functions, including pathogenesis of arthritic diseases (34, 44). The proliferation of synoviocytes from patients with RA has been reported to be suppressed by PLC and PKC inhibitors (44). In our previous research, we found that the PLC/PKC pathway was involved in thrombin-induced interleukin-6 synthesis in rheumatoid synovial cells (45).
However, the impact of these molecules on synovium-induced angiogenesis is not clear. In OA-related research, APLN increased angiogenesis responses, including endothelial cell migration, proliferation, and the capillary tube-like structure formation of endothelial cells (19, 46). Our investigations found that PLC and PKC inhibitors reduced APLN-enhanced Ang1 expression in RASFs and EPC angiogenesis. This was confirmed by findings from genetic siRNA experiments demonstrating that PLCγ and PKCα mediate the angiogenic effects of APLN. Treatment of RASFs with APLN also augmented PLCγ and PKCα phosphorylation. This suggests that PLCγ and PKCα activation are controlled by APLN-dependent Ang1 angiogenesis in EPCs. Recent publications have described how PKCδ activation regulates lymphangiogenesis and angiogenesis in RASFs and LEC cells (31, 47). However, our study showed that neither the PKCδ inhibitor (Rottlerin) nor the genetic siRNA affected APLN-facilitated expression of Ang1 and angiogenesis in EPCs, indicating that the PKCδ pathway is not involved in APLN-regulated angiogenic effects. Thus, PKCα but not PKCδ activation regulates APLN-induced Ang1 expression and EPC angiogenesis.

MiRNAs post-transcriptionally regulate gene expression (48). In RA, aberrant miRNA expression regulates the expression of inflammatory pathways (35, 36). Numerous miRNAs also control angiogenesis during RA progression (49). MiR-525-5p has been implicated in multiple cancers, including for instance glioma (50), cervical cancer (51) and NSCLC (52), but no evidence to date has indicated the involvement of miR-525-5p with RA progression. In this study, stimulation of RASFs with APLN inhibited miR-525-5p expression and transfecting them with miR-525-5p mimic antagonized APLN-promoted upregulation of Ang1 expression and EPC angiogenesis. It has been reported that transcriptional and post-transcriptional regulation play key roles in miRNA activation and inhibition (53). In this study, treating RASFs with PLCγ and PKCα inhibitors reversed APLN-promoted inhibition of miR-525-5p expression, which suggests that APLN may assist with Ang1 production and EPC angiogenesis by inhibiting miR-525-5p synthesis via the PLCγ and PKCα signaling cascades. Whether PLCγ/PKCα signaling regulates miR-525-5p expression through transcriptional or post-transcriptional regulation needs further examination.

In conclusion, we have determined that APLN increases Ang1 synthesis and subsequently facilitates EPC angiogenesis by suppressing miR-525-5p synthesis via PLCγ and PKCα signaling (Figure 7). The evidence supports the targeting of the APLN-dependent miR-525-5p/Ang1 axis in RA treatment regimens.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by CMUH108-REC3-039. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by CMU IACUC-2019-330.

AUTHOR CONTRIBUTIONS
C-HTa, H-PL, and C-JH initiated the research project. Y-HZ, S-CL, C-CH, C-HTs, and S-WW performed the research. C-CH, C-HTs, and S-WW provided the material. C-HTa wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by grants from the Ministry of Science and Technology in Taiwan (MOST 110-2320-B-039-022-MY3; MOST 110-2314-B-039-008; MOST 110-2314-B-039-012; MOST 110-2314-B-195-003), China Medical University Beigang Hospital (110CMUBHR-07 and 110CMUBHR-11) and China Medical University Hospital (DMR-110-074).

ACKNOWLEDGMENTS
We would like to thank Iona J. MacDonald from China Medical University for her editing of this manuscript.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.737990/full#supplementary-material

REFERENCES
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. Lancet (2016) 388 (10055):2023–38. doi: 10.1016/S0140-6736(16)30173-8
2. MacDonald IJ, Liu SC, Su CM, Wang YH, Tsai CH, Tang CH. Implications of Angiogenic Factors and Cytokines on Angiogenic Function of Endothelial Progenitor Cells: A Review of In Vitro Human Studies. Growth Factors (2014) 32(3-4):83–116. doi: 10.3109/08977194.2014.904300
3. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization. Circ Res (1999) 85(3):221–8. doi: 10.1161/01.RES.85.3.221
4. Peplow PV. Influence of Growth Factors and Cytokines on Angiogenic Function of Endothelial Progenitor Cells. A Review of In Vitro Human Studies. Circ Res (2014) 116:83–116. doi: 10.1161/01.RES.85.3.221
5. Su CM, Hsu CJ, Tsai CH, Huang CY, Wang SW, Tang CH. Resistin Promotes Angiogenesis in Endothelial Progenitor Cells Through Inhibition of MicroRNA206: Potential Implications for Rheumatoid Arthritis. Stem Cells (2015) 33(7):2243–55. doi: 10.1002/stem.2024
6. Chen CY, Su CM, Hsu CJ, Huang CC, Wang SW, Liu SC, et al. CCN1 Promotes VEGF Production in Osteoblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-126 Expression in Rheumatoid Arthritis. *J Bone Miner Res* (2017) 32(1):34–45. doi: 10.1002/jbmr.2926

7. Carmeliet P, Jain RK. Molecular Mechanisms and Clinical Applications of Angiogenesis. *Nature* (2011) 473(7347):298–307. doi: 10.1038/nature10144

8. Wei SM, Cheres DA. Tumor Angiogenesis: Molecular Pathways and Therapeutic Targets. *Nat Med* (2011) 17(11):1359–70. doi: 10.1038/nm.2357

9. Brindle NP, Safari P, Alitalo K. Signaling and Functions of Angiopoietins. *Circ Res* (2006) 98(10):1014–23. doi: 10.1161/01.RES.0000218275.54089.12

10. Kinjo T, Higashi H, Uno K, Kuramoto N. Apelin/Apelin Receptor System: Molecular Characteristics, Physiological Roles, and Prospects as a Target for Disease Prevention and Pharmacotherapy. *Carr Mol Pharmacol* (2021) 14 (2):210–9. doi: 10.2174/1847467213666200602133032

11. Zhou Q, Cao J, Chen L. Apelin/APJ System: A Novel Therapeutic Target for Oxidative Stress-Related Inflammatory Diseases (Review). *Int J Mol Med* (2016) 37(5):1159–69. doi: 10.3892/ijmm.2016.2544

12. MacDonald II, Liu SC, Huang CC, Kuo SJ, Tsai CH, Tang CH. Associations Between Adipokines in Arthritis Disease and Implications for Obesity. *Int J Mol Sci* (2019) 20(6):1505–22. doi: 10.3390/ijms20061505

13. Hu PF, Chen WP, Tang JL, Bao JP, Wu LD. Apelin Plays a Catabolic Role on Synovial Fibroblasts in the Progression of Osteoarthritis by Regulating VEGF-Dependent Angiogenesis and miR-150-5p Expression in Human Synovial Fibroblasts. *J Cell Physiol* (2020) 12(10):9224–39. doi: 10.18632/jcellphysiol.103195

14. Gunter S, Solomon A, Tsang L, Woodiwiss AJ, Robinson C, Millen AM, et al. Apelin Concentrations Are Associated With Altered Atherosclerotic Plaque Stability Mediator Levels and Atherosclerosis in Rheumatoid Arthritis. *Atherosclerosis* (2017) 256:75–81. doi: 10.1016/j.atherosclerosis.2016.11.024

15. O’Brien J, Hayden H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol* (2018) 9:12. doi: 10.3389/fendo.2018.00049

16. Mousavi MJ, Jamshidi A, Chopra A, Aslani S, Milani AM, et al. Apelin Concentrations Are Associated With Altered Atherosclerotic Plaque Stability Mediator Levels and Atherosclerosis in Rheumatoid Arthritis. *Atherosclerosis* (2017) 256:75–81. doi: 10.1016/j.atherosclerosis.2016.11.024

17. Kiewisz J, Kaczmarek MM, Pawlowska A, Kmiec Z, Stompor T. Endothelial b and AP-1 Signalling Attenuates TNF-Alpha and IL-1beta Expression in Synovial Fibroblasts and Promotes Angiogenesis by Inhibiting miR-206 via FAK/C-Src/PP2Delta Pathway. *Cancer Lett* (2017) 385:261–70. doi: 10.1016/j.canlet.2016.10.010

18. Patel J, Donovan P, Khosrotehrani K. Concise Review: Functional De

19. Wang LH, Tsai HC, Cheng YC, Lin CY, Huang YL, Tsai CH, et al. CTGF Promotes Osteosarcoma Angiogenesis by Regulating miR-543/Angiopoietin 2 Signaling. *Cancer Lett* (2017) 391:28–37. doi: 10.1016/j.canlet.2017.01.013

20. Zhang L, Xu H, Zhao M, Chang C, Lu Q. Clinical Significance of miRNAs in Autoimmunity. *J Autoimmun* (2020) 109:102438. doi: 10.1016/j.jaut.2020.102438

21. Wang Y, Yan S, Yang J, Lu H, Xu D, Wang Z. Non-Coding RNAs in Rheumatoid Arthritis: From Bench to Bedside. *Front Immunol* (2019) 10:3239. doi: 10.3389/fimmu.2019.03129

22. Mckinnon IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. *N Engl J Med* (2011) 365(23):2205–9. doi: 10.1056/NEJMra1004956

23. Catrina AI, Svensson CI, Malmstrom V, Schett G, Klareskog L. Mechanisms Leading From Systemic Autoimmunity to Joint-Specific Disease in Rheumatoid Arthritis. *Nat Rev Rheumatol* (2017) 13(2):79–86. doi: 10.1038/nrrheum.2016.200

24. Hayashi S, Rakugi H, Morishita R. Insight Into the Role of Angiopoietins in Aging-Associated Diseases. *Cells* (2020) 9(12):2636–51. doi: 10.3390/cells9122636

25. Patel J, Donovan P, Khosrotehrani K. Concise Review: Functional De

26. Chen SY, Huang CY, Tsai CH, Wang SW, Lin YM, Tang CH. Interleukin-1beta Induces Fibroblast Growth Factor 2 Expression and Subsequently Promotes Endothelial Progenitor Cell Angiogenesis in Chondrocytes. *Clin Sci* (2016) 130(9):667–81. doi: 10.1042/CS20150622

27. Furuhashi I, Abe K, Sato T, Inoue H. Thrombin-Stimulated Proliferation of Cultured Human Synovial Fibroblasts Through Proteolytic Activation of Metalloprotease-13 Production in Lung Cancer Cells. *Biochem Pharmacol* (2018) 155:537–46. doi: 10.1016/j.bcp.2018.07.024

28. Lee H-P, Liao C-C, Tsai CH, Wang SW, Lin YM, Tang CH. Interleukin-1beta Induces Fibroblast Growth Factor 2 Expression and Subsequently Promotes Endothelial Progenitor Cell Angiogenesis in Chondrocytes. *Clin Sci* (2016) 130(9):667–81. doi: 10.1042/CS20150622
45. Chiu YC, Fong YC, Lai CH, Hung CH, Hsu HC, Lee TS, et al. Thrombin-Induced IL-6 Production in Human Synovial Fibroblasts Is Mediated by PAR1, Phospholipase C, Protein Kinase C Alpha, C-Src, NF-Kappa B and P300 Pathway. *Mol Immunol* (2008) 45(6):1587–99. doi: 10.1016/j.molimm.2007.10.004
46. Wen Y, Chen R, Zhu C, Qiao H, Liu Y, Ji H, et al. MiR-503 Suppresses Hypoxia-Induced Proliferation, Migration and Angiogenesis of Endothelial Progenitor Cells by Targeting Apelin. *Peptides* (2018) 105:58–65. doi: 10.1016/j.peptides.2018.05.008
47. Tai HC, Lee TH, Tang CH, Chen LP, Chen WC, Lee MS, et al. Phomaketide A Inhibits Lymphangiogenesis in Human Lymphatic Endothelial Cells. *Marine Drugs* (2019) 17(4):215–30. doi: 10.3390/md17040215
48. Nugent M. MicroRNAs: Exploring New Horizons in Osteoarthritis. *Osteoarthritis Cartilage* (2016) 24(4):573–80. doi: 10.1016/j.joca.2015.10.018
49. Tiwari A, Mukherjee B, Dixit M. MicroRNA Key to Angiogenesis Regulation: MicroRNA Biology and Therapy. *Curr Cancer Drug Targets* (2018) 18(3):266–77. doi: 10.2174/1568009617666170630142725
50. Xie P, Han Q, Liu D, Yao D, Lu X, Wang Z, et al. miR-525-5p Modulates Proliferation and Epithelial-Mesenchymal Transition of Glioma by Targeting Stat-1. *Onco Targets Ther* (2020) 13:9957–66. doi: 10.2147/OTT.S257951
51. Chen M, Liu LX. MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis. *Dig Dis Sci* (2020) 65(8):2442–51. doi: 10.1007/s10620-019-05916-9
52. Wu X, Li M, Li Y, Deng Y, Ke S, Li F, et al. Fibroblast Growth Factor 11 (FGF11) Promotes Non-Small Cell Lung Cancer (NSCLC) Progression by Regulating Hypoxia Signaling Pathway. *J Transl Med* (2021) 19(1):353.
53. Ambros V. The Functions of Animal microRNAs. *Nature* (2004) 431 (7006):350–5. doi: 10.1038/nature02871

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chang, Zhong, Liu, Huang, Tsai, Lee, Wang, Hsu and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.